| Literature DB >> 28587319 |
Abstract
Drowning is a crucial public safety problem and is the third leading cause of accidental fatality, claiming ~372,000 lives annually, worldwide. In near-drowning patients, acute lung injury (ALI) or acute respiratory distress syndrome (ARDS) is one of the most common complications. Approximately 1/3 of near-drowning patients fulfill the criteria for ALI or ARDS. In the present article, the current literature of near-drowning, pathophysiologic changes and the molecular mechanisms of seawater-drowning-induced ALI and ARDS was reviewed. Seawater is three times more hyperosmolar than plasma, and following inhalation of seawater the hyperosmotic seawater may cause serious injury in the lung and alveoli. The perturbing effects of seawater may be primarily categorized into insufficiency of pulmonary surfactant, blood-air barrier disruption, formation of pulmonary edema, inflammation, oxidative stress, autophagy, apoptosis and various other hypertonic stimulation. Potential treatments for seawater-induced ALI/ARDS were also presented, in addition to suggestions for further studies. A total of nine therapeutic strategies had been tested and all had focused on modulating the over-activated immunoreactions. In conclusion, seawater drowning is a complex injury process and the exact mechanisms and potential treatments require further exploration.Entities:
Keywords: acute lung injury; acute respiratory distress syndrome; near-drowning; seawater
Year: 2017 PMID: 28587319 PMCID: PMC5450642 DOI: 10.3892/etm.2017.4302
Source DB: PubMed Journal: Exp Ther Med ISSN: 1792-0981 Impact factor: 2.447
Seawater-induced changes.
| Name | Category | Cell/tissue | Change | (Refs.) |
|---|---|---|---|---|
| B cell lymphoma-2 | Apoptosis-related protein | ↑P | ( | |
| Cleaved caspase-3 | Apoptosis-related protein | ↑P | ( | |
| Cleaved caspase-8 | Apoptosis-related protein | ↑P | ( | |
| Fas | Apoptosis-related protein | ↑P | ( | |
| FasL | Apoptosis-related protein | ↑P | ( | |
| 4E-BP1 | Binding protein | AEC | ↑Ph | ( |
| AQP1 | Channel | ↑R,P | ( | |
| AQP5 | Channel | ↑R,P | ( | |
| α-ENaC | Channel | ↓R | ( | |
| IL-10 | Cytokine | In vivo | ↑P | ( |
| IL-1β | Cytokine | ↑P | ( | |
| IL-6 | Cytokine | ↑P | ( | |
| IL-8 | Cytokine | ↑P | ( | |
| MIF | Cytokine | ↑P | ( | |
| TNF-α | Cytokine | ↑P | ( | |
| MPO | Enzyme | ↑A | ( | |
| MYPT-1 | Enzyme | ↑Ph | ( | |
| T-SOD | Enzyme | ↓A | ( | |
| VEGF | Growth regulator | ↑R,P | ( | |
| Akt | Kinase | ↑Ph | ( | |
| ATM | Kinase | AEC | ↑Ph | ( |
| eIF4E | Kinase | AEC | ↑Ph | ( |
| JAK1 | Kinase | NR8383 | ↑Ph | ( |
| JAK2 | Kinase | NR8383 | ↑Ph | ( |
| p70S6K1 | Kinase | AEC | ↑Ph | ( |
| PI3K | Kinase | AEC | ↑Ph | ( |
| PKC | Kinase | ↑Ph | ( | |
| ERK1/2 | MAP kinase | ↑Ph | ( | |
| p38 | MAP kinase | AEC | ↑Ph | ( |
| LC3 | Microtubule associated protein | ↑R | ( | |
| LC3-II | Microtubule associated protein | ↑P | ( | |
| SEMA7A | Neuronal guidance protein | ↑P | ( | |
| MDA | Peroxidation product | ↑A | ( | |
| NE | Protease | ↑P | ( | |
| ERβ | Receptor | ↓P | ( | |
| sVEGFR1 | Receptor | ↑P | ( | |
| VDR | Receptor | ↑R, P | ( | |
| S6 ribosomal | Ribosomal protein | AEC | ↑Ph | ( |
| SP-A | Secretory protein | ↓R | ( | |
| GTP-RhoA | Signaling G protein | ↑P | ( | |
| HIF-1α | Transcription factor | ↑P | ( | |
| NF-κB | Transcription factor | ↑Ph, TL | ( | |
| STAT1 | Transcription factor | ↑P, Ph | ( | |
| Cx43 | Transmembrane channel | ↑R, Ph | ( | |
| Cx43 | Transmembrane channel | ↓P | ( | |
| Na+/K+-ATPase | Transporter | ↓A, P | ( |
4E-BP, eukaryotic translation initiation factor 4E binding protein 1; AQP, aquaporin; α-ENaC, epithelial sodium channel subunit alpha; IL, interleukin; MIF, macrophage migration inhibitory factor; TNF-α, tumor necrosis factor alpha; MPO, myeloperoxidase; MYPT-1, myosin light-chain phosphatase-1; T-SOD, total superoxide dismutase; VEGF, vascular endothelial growth factor; Akt, protein kinase B; eIF4E, eukaryotic translation initiation factor 4E; JAK, janus kinase; P70S6K1, ribosomal protein S6 kinase beta-1; PI3K, phosphatidylinositol-4,5-bisphosphate 3-kinase; PKC, protein kinase C; ERK, extracellular signal-regulated kinase; LC3, microtubule-associated protein 1 light chain 3 alpha; SEMA7A, semaphorin 7A; MDA, malondialdehyde; NE, neutrophil elastase; ERβ, estrogen receptor beta; sVEGFR1, soluble vascular endothelial growth factor receptor 1; VDR, vitamin D receptor; SP-A, secretory protein A; GTP-RhoA, guanosine-5′-triphosphate-ras homolog gene family member A; HIF-1α, hypoxia-inducible factor 1-alpha; NF-κB, nuclear factor-kappa B; STAT1, signal transducer and activator of transcription 1; Cx43, connexin 43; A, activity; P, protein abundance; Ph, phosphorylation; A, activity; R, mRNA abundance; TL, translocation; PAT2, primary alveolar type II cells; AEC, alveolar epithelial cells; RPMVECs, rat pulmonary microvascular endothelial cells.
Treatment of seawater-induced acute lung injury.
| Name | Category | Cell/tissue | Target | Dose | Time | Refs. |
|---|---|---|---|---|---|---|
| Dexamethasone | Anti-inflammation | Na+/K+-ATPase, SP-A, α-ENaC | 1 mg/kg | Post-treated | ( | |
| Tanshinone II A | Anti-edema | AQP1, AQP5 | 50 mg/kg, 25 µg/ml | Post-treated | ( | |
| Tanshinone II A | Anti-inflammation | MIF, NF-κB | 10 mg/kg, 20 µg/ml | Post-treated | ( | |
| Tanshinone II A | Anti-apoptosis | Bcl-2, Caspase-3, Akt, ERK1/2 | 50 mg/kg | Post-treated | ( | |
| 17β-Estradiol | Anti-edema | ERβ, AQP1, AQP5 | 5 mg/kg | Post-treated | ( | |
| Urinary trypsin inhibitor | Anti-inflammation | NF-κB, NE | 50,000 U/kg | Post-treated | ( | |
| 3,5,4′-Tri-O-acetylresveratrol | Anti-inflammation, snti-oxidative | NF-κB, HIF-1α | 150 mg/kg, 450 mg/kg | Pretreated | ( | |
| 3,5,4′-Tri-O-acetylresveratrol | Cell-interaction | Connexin 43 | 50 mg/kg. 150 mg/kg, 450 mg/kg | Pretreated | ( | |
| Epigallocatechin-3-gallate | Anti-inflammation | STAT1, JAK1, JAK2 | 10 mg/kg | Pretreated | ( | |
| 4-hydroxyphenylacetic acid | Anti-inflammation, | HIF-1α, p70S6K1, S6 ribosomal, 4E-BP1, eIF4E | 50 mg/kg, 100 mg/kg, 150 mg/kg | Pretreated anti-edema | ( | |
| 1α,25-Dihydroxyvitamin D3 | Anti-inflammation | NF-κB, RhoA, MYPT1 | 1 µg/kg, 5 µg/kg, 25 µg/kg | Pretreated | ( | |
| BMSCs | Anti-autophagy | LC3 | 2×106 cells | Post-treated | ( |
Bcl-2, B cell lymphoma-2; AQP, aquaporin; α-ENaC, epithelial sodium channel subunit alpha; MIF, macrophage migration inhibitory factor; MYPT-1, myosin light-chain phosphatase-1; Akt, protein kinase B; eIF4E, eukaryotic translation initiation factor 4E; JAK, janus kinase; P70S6K1, ribosomal protein S6 kinase beta-1; LC3, microtubule-associated protein 1 light chain 3 alpha; NE, neutrophil elastase; ERβ, estrogen receptor beta; SP-A, secretory protein A; RhoA, ras homolog gene family member A; HIF-1α, hypoxia-inducible factor 1-alpha; NF-κB, nuclear factor-kappa B; STAT1, signal transducer and activator of transcription 1; Cx43, connexin 434 E-BP1, eukaryotic translation initiation factor 4E binding protein 1. RPMVEC, rat pulmonary microvascular endothelial cells.